Építés alatt – nem éles oldal
Belépés

NCT05421832Befejeződött

A Novel Measurement Concept to Objectively Quantify Severity of Vocal and Speech Related Symptoms Associated With Parkinson's Disease

Forrás: ClinicalTrials.gov · Utoljára frissítve: 2025. júl. 24.

Következő lépések

Rövid összefoglaló (regiszter, angolul)

The aim of this research program is to develop and validate a smartphone app-based digital measurement concept that: * Objectively quantifies the severity of Parkinson's Disease (PD) related vocal and speech symptoms; * Accurately and sensitively identifies vocal and speech abnormalities associated with the prodromal stage of PD.

Állapot (regiszter)
Befejeződött
Vizsgálattípus
Megfigyeléses
Résztvevők száma
91 (tényleges)
Első benyújtás
2022. jún. 8.
Kezdés
2022. szept. 27.
Elsődleges befejezés
2025. jún. 30.
Fő szponzor
Northwestern University
Betegségek
Parkinson-kór
NCT-szám
NCT05421832

Mit vállalsz

  • Vizsgálat típusa: Megfigyeléses
  • Bevont résztvevők: 91
  • 2022. szept. 27. és az elsődleges befejezés (2025. jún. 30.) között
  • 1 helyszín, 1 országban
  • Vizitek és vizsgálatok: kérdezd a vizsgálat csapatát, a regiszter nem sorolja fel őket

A(z) ClinicalTrials.gov regisztermezőiből összeállítva. A vizsgálat felépítését írja le.

Ki nem vehet részt

Szó szerint a(z) ClinicalTrials.gov forrásból, témák szerint csoportosítva. Hogy ki vehet részt, azt csak a vizsgálat csapata dönti el.

Korábbi kezelés

  • History of drug and/or alcohol abuse within the past year prior to Screening Visit.
  • Previously obtained MRI scan with evidence of clinically significant neurological disorder (in the opinion of the Investigator).
  • History of drug and/or alcohol abuse within the past year prior to Screening Visit.
  • Previously obtained MRI scan with evidence of clinically significant neurological disorder (in the opinion of the Investigator).
  • History of drug and/or alcohol abuse within the past year prior to Screening Visit.

Más betegség

  • Symptomatic or atypical PD syndromes due to either drugs (e.g., metoclopramide, flunarizine, neuroleptics) or metabolic disorders (e.g., Wilson's disease), encephalitis, or degenerative diseases (e.g., progressive supranuclear palsy).
  • Current or active clinically significant neurological disorder other than PD (in the opinion of the Investigator).
  • Significant cognitive impairment or clinical dementia at Screening that, in the opinion of the Investigator, would interfere with study evaluation.
  • Any other medical or psychiatric condition, which in the opinion of the investigator might preclude participation.
    • Prodromal PD:
  • Clinical diagnosis of PD, other parkinsonism, or dementia.
  • Any current or active clinically significant neurological disorder (in the opinion of the Investigator).
  • Significant cognitive impairment or clinical dementia at Screening that, in the opinion of the Investigator, would interfere with study evaluation.
  • Any current or active clinically significant neurological disorder (in the opinion of the Investigator).
  • Significant cognitive impairment or clinical dementia at Screening that, in the opinion of the Investigator, would interfere with study evaluation.
  • Any other medical or psychiatric condition, which in the opinion of the investigator might preclude participation

Életkor

  • Any other medical or psychiatric condition, which in the opinion of the investigator might preclude participation.
    • Age \& Sex Matched Healthy Control:

Egyéb

  • PD:
  • Late-stage PD diagnosis (i.e., Hoehn \& Yahr Stage 5) at Screening Visit
  • Inability or unwillingness to complete all aspects of the study - including use of a provisioned smartphone for study assessments; completion of telehealth assessments.
  • Inability or unwillingness to complete all aspects of the study - including use of a provisioned smartphone for study assessments; completion of telehealth assessments.
  • First degree relative with PD (i.e., biologic parent, sibling, child).
  • Inability or unwillingness to complete all aspects of the study - including use of a provisioned smartphone for study assessments; completion of telehealth assessments.

Kiket keres a vizsgálat

  • PD:
  • Male or female age 30 years or older at Screening Visit.
  • Diagnosis of PD as defined by MDS PD diagnostic criteria [1]
  • PD severity at Screening Visit of either:
    • PD Hoehn and Yahr Stage 1-2, inclusive (PD Cohort I)
    • PD Hoehn and Yahr Stages 3-4, inclusive (PD Cohort II)
  • Able and willing to complete all aspects of the study, including at home smartphone app and Zoom telehealth assessments.
  • Able to provide informed consent.
    • Prodromal PD:
  • Confirmation that participant is eligible based on clinician determined predictive criteria of known risk of PD including
    • Rapid eye movement sleep behavior disorder (RBD), possible, probable or definite, OR
    • Hyposmia defined as less than 10th percentile on University of Pennsylvania Smell Identification Test (UPSIT), age and gender adjusted, OR
    • Known genetic variants associated with PD risk, AND Confirmed eligible DAT scan.
  • Male or female age 30 or older at Screening Visit.
  • Able and willing to complete all aspects of the study, including at home smartphone app and Zoom telehealth assessments
  • Able to provide informed consent.
    • Age \& Sex Matched Healthy Control:
  • Male or female age 30 years or older at Screening visit.
  • Able and willing to complete all aspects of the study, including at home smartphone app and Zoom telehealth assessments
  • Able to provide informed consent.

Életkor a regiszterben: 30 év – - · Nem: nők és férfiak · Egészséges önkénteseket is fogad

A teljes feltétellista: ClinicalTrials.gov

Helyszínek (1)

Helyszínek a regiszter sorrendjében. Ha a profilodba mented a városodat, távolság szerint rendeződnek.

HelyszínVárosOrszágHelyszín állapota
Northwestern UniversityChicagoEgyesült ÁllamokIsmeretlen állapot

Te vagy a koordinátor? Erősítsd meg az adatokat

Ez az oldal tájékoztatás, nem orvosi tanács. Bármely vizsgálatról az orvosoddal beszélj.